Claims
- 1. A method of screening for an agent that inhibits mononuclear phagocyte - plaque component complex formation comprising:
contacting a mononuclear phagocyte with an effective amount of a plaque component to stimulate mononuclear phagocyte-plaque component complex formation, and an effective amount of an agent suspected of inhibiting said complex formation, for an effective amount of time, measuring of mononuclear phagocyte-plaque component complex formation, comparing said measured mononuclear phagocyte-plaque component complex formation to a measured control, wherein reduction of mononuclear phagocyte-plaque component complex formation compared to said control results in detection of an agent that inhibits mononuclear phagocyte-plaque component complex formation.
- 2. A method of claim 1 wherein said agent is a plaque suppressor.
- 3. A method of claim 1 wherein said plaque component is selected from the group consisting of β amyloid and active fragments thereof, α-antichymotrypsin, apolipoprotein A, apolipoprotein E, glycoproteins, heparan sulfate, and proteases.
- 4. A method of claim 1 wherein said plaque component is β amyloid and said agent is a plaque suppressor.
- 5. A method of claim 1 wherein said plaque component or said mononuclear phagocyte is adhered to a solid support to form an plaque component adhered solid support.
- 6. A method of claim 5 wherein said solid support is selected from a microsphere, liposome, sepharose, and sephadex.
- 7. A method of claim 5 wherein said plaque component is β amyloid and said solid support is a microsphere.
- 8. A method of claim 5 wherein said β amyloid is adhered to a solid support and is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 9. A method of claim 1 wherein said plaque component or said mononuclear phagocyte is labeled.
- 10. A method of claim 9 wherein said label is selected from the group consisting of 32P, 125I, 14C, 3H, 35S, biotin, fluorescein, rhodamine, peroxidase, and antibody labeling.
- 11. A method of claim 1 wherein said step of measuring is selected from the group consisting of imaging said mononuclear phagocyte-plaque component complex, and detecting amplified nucleic acids from said mononuclear phagocyte of said mononuclear phagocyte-plaque component complex.
- 12. A method of claim 1 wherein said step of measuring comprises imaging said mononuclear phagocyte-plaque component complex and observing a signal resulting from said imaging.
- 13. A method of claim 1 wherein said step of measuring comprises detecting amplified nucleic acids from said mononuclear phagocyte-plaque component complex.
- 14. A method of claim 1 wherein said plaque component is isolated from a patient suspected of having a disease selected from the group consisting of Alzheimer Disease, hereditary hemorrhage with amyloidosis-Dutch type, cerebral amyloid angiopathy, cerebral amyloid angiopathy, Down's syndrome, spongiform encephalopathy, Creutzfeld-Jakob disease, HIV, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, and trauma.
- 15. A method of claim 1 wherein said plaque component or said mononuclear phagocyte is adhered to a solid support to form an plaque component adhered solid support which is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 16. A method of screening for an agent that inhibits mononuclear phagocyte - plaque component complex formation comprising:
contacting a mononuclear phagocyte with an effective amount of a plaque component to stimulate mononuclear phagocyte - plaque component complex formation, wherein said plaque component is coupled to a solid support, and an effective amount of an agent suspected of inhibiting said complex formation, for an effective amount of time, measuring of mononuclear phagocyte - plaque component complex formation, comparing said measured mononuclear phagocyte - plaque component complex formation to a measured control, wherein reduction of mononuclear phagocyte - plaque component complex formation compared to said control results in detection of an agent that inhibits mononuclear phagocyte - plaque component complex formation.
- 17. A method of screening for an agent that inhibits mononuclear phagocyte - plaque component complex formation comprising:
contacting a mononuclear phagocyte in a mammalian brain with an effective amount of a plaque component to stimulate mononuclear phagocyte - plaque component complex formation, wherein said plaque component is coupled to a solid support, and an effective amount of an agent suspected of inhibiting said complex formation, for an effective amount of time, measuring of mononuclear phagocyte - plaque component complex formation, comparing said measured mononuclear phagocyte - plaque component complex formation to a measured control, wherein reduction of mononuclear phagocyte - plaque component complex formation compared to said control results in detection of an agent that inhibits mononuclear phagocyte - plaque component complex formation.
- 18. A method of claim 17 wherein said step of measuring is selected from the group consisting of imaging said mononuclear phagocyte-plaque component complex, and detecting nucleic acids from said mononuclear phagocyte of said mononuclear phagocyte-plaque component complex.
- 19. A method of claim 17 wherein said plaque component or said mononuclear phagocyte is labeled.
- 20. A method of claim 19 wherein said label is selected from the group consisting of 32P, 125I, 14C, 3H, 35S, biotin, fluorescein, rhodamine, peroxidase, and antibody labeling.
- 21. A method of claim 17 wherein said step of measuring comprises imaging said mononuclear phagocyte-plaque component complex and observing a signal resulting from said imaging.
- 22. A method of claim 17 wherein said step of measuring comprises detecting amplified nucleic acids from said mononuclear phagocyte-plaque component complex.
- 23. A method of claim 1 wherein said mononuclear phagocyte is selected from the group consisting of a microglial cell, a monocyte, a macrophage, and a microglial precursor cell, monocyte precursor cell, and a macrophage precursor cell.
- 24. A method of screening for an agent that inhibits plaque component activation of a mononuclear phagocyte comprising:
contacting a mononuclear phagocyte with an effective amount of a plaque component to stimulate plaque component activation of said mononuclear phagocyte, and an effective amount of an agent suspected of inhibiting said activation, for an effective amount of time, measuring plaque component activation of said mononuclear phagocyte, comparing said plaque component activation of said measured mononuclear phagocyte to a measured control, wherein reduction of plaque component activation of said mononuclear phagocyte compared to said control results in detection of an agent that inhibits plaque component activation of said mononuclear phagocyte.
- 25. A method of claim 24 wherein said agent is a mononuclear phagocyte inactivator.
- 26. A method of claim 24 wherein said plaque component is selected from the group consisting of β amyloid and active fragments thereof, α-antichymotrypsin, apolipoprotein A, apolipoprotein E, glycoproteins, heparan sulfate, and proteases.
- 27. A method of claim 24 wherein said plaque component is β amyloid and said agent is a mononuclear phagocyte inactivator.
- 28. A method of claim 24 wherein said plaque component or said mononuclear phagocyte is adhered to a solid support to form an plaque component adhered solid support.
- 29. A method of claim 28 wherein said solid support is selected from a microsphere, liposome, sepharose, and sephadex.
- 30. A method of claim 28 wherein said plaque component is β amyloid and said solid support is a microsphere.
- 31. A method of claim 27 wherein said p amyloid is adhered to a solid support and is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 32. A method of claim 24 wherein said plaque component or said mononuclear phagocyte is labeled.
- 33. A method of claim 32 wherein said label is selected from the group consisting of 32P, 125I, 14C, 3H, 35S, biotin, fluorescein, rhodamine, peroxidase, and antibody labeling.
- 34. A method of claim 24 wherein said step of measuring is selected from the group consisting of imaging said mononuclear phagocyte, detecting amplified nucleic acids from said mononuclear phagocyte, observing altered mononuclear phagocyte morphology, observing the expression of cell surface molecules on said mononuclear phagocyte, and observing the release of nitric oxide, free radicals, cytokines, lipoproteins, enzymes, and proteins from said mononuclear phagocyte.
- 35. A method of claim 24 wherein said step of measuring comprises imaging said mononuclear phagocyte and observing a signal resulting from said imaging.
- 36. A method of claim 24 wherein said step of measuring comprises detecting amplified nucleic acids from said mononuclear phagocyte.
- 37. A method of claim 24 wherein said mononuclear phagocyte is a mononuclear phagocyte selected from a patient suspected of having a disease selected from Alzheimer Disease, hereditary hemorrhage with amyloidosis-Dutch type, cerebral amyloid angiopathy, cerebral amyloid angiopathy, Down's syndrome, spongiform encephalopathy, Creutzfeld-Jakob disease, HIV, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, and trauma.
- 38. A method of claim 24 wherein said plaque component or said mononuclear phagocyte is adhered to a solid support to form an plaque component adhered solid support which is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 39. A method of screening for an agent that inhibits plaque activation of a mononuclear phagocyte comprising:
contacting a mononuclear phagocyte with an effective amount of a plaque component to stimulate plaque component activation of said mononuclear phagocyte, wherein said plaque component is coupled to a solid support, and an effective amount of an agent suspected of inhibiting said activation, for an effective amount of time, measuring plaque component activation of said mononuclear phagocyte, comparing said plaque component activation of said measured mononuclear phagocyte to a measured control, wherein reduction of plaque component activation of said mononuclear phagocyte compared to said control results in detection of an agent that inhibits plaque component activation of said mononuclear phagocyte.
- 40. A method of screening for an agent that inhibits plaque activation of a mononuclear phagocyte comprising:
contacting a mononuclear phagocyte in a mammalian brain with an effective amount of a plaque component to stimulate plaque component activation of said mononuclear phagocyte, wherein said plaque component is coupled to a solid support, and an effective amount of an agent suspected of inhibiting said activation, for an effective amount of time, measuring plaque component activation of said mononuclear phagocyte, comparing said plaque component activation of said measured mononuclear phagocyte to a measured control, wherein reduction of plaque component activation of said mononuclear phagocyte compared to said control results in detection of an agent that inhibits plaque component activation of said mononuclear phagocyte.
- 41. A method of claim 40 wherein said step of measuring is selected from the group consisting of imaging said mononuclear phagocyte, detecting amplified nucleic acids from said mononuclear phagocyte, observing altered mononuclear phagocyte morphology, observing the expression of cell surface molecules on said mononuclear phagocyte, and observing the release of nitric oxide, free radicals, cytokines, lipoproteins, enzymes, and proteins from said mononuclear phagocyte.
- 42. A method of claim 40 wherein said plaque component or said mononuclear phagocyte is labeled.
- 43. A method of claim 42 wherein said label is selected from the group consisting of 32P, 125I, 14C, 3H, 35S, biotin, fluorescein, rhodamine, peroxidase, and antibody labeling.
- 44. A method of claim 40 wherein said step of measuring comprises imaging said mononuclear phagocyte and observing a signal resulting from said imaging.
- 45. A method of claim 40 wherein said step of measuring comprises detecting amplified nucleic acids from said mononuclear phagocyte.
- 46. A method of claim 24 wherein said mononuclear phagocyte is selected from the group consisting of a microglial cell, a monocyte, a macrophage, and a microglial precursor cell, monocyte precursor cell, and a macrophage precursor cell.
- 47. A method of screening for an agent that inhibits plaque component induced neurotoxicity of a mononuclear phagocyte comprising:
contacting a mononuclear phagocyte with an effective amount of a plaque component to stimulate plaque component induced neurotoxicity, and an effective amount of an agent suspected of inhibiting said plaque component induced neurotoxicity of a mononuclear phagocyte for an effective amount of time, measuring plaque component induced neurotoxicity of said mononuclear phagocyte, comparing said measured plaque component induced neurotoxicity to a measured control, wherein reduction of plaque component induced neurotoxicity compared to said control results in detection of an agent that inhibits plaque component induced neurotoxicity of a mononuclear phagocyte.
- 48. A method of claim 47 wherein said agent is an inactivator of neurotoxic mononuclear phagocytes.
- 49. A method of claim 47 wherein said plaque component is selected from the group consisting of β amyloid and active fragments thereof, α-antichymotrypsin, apolipoprotein A, apolipoprotein E, glycoproteins, heparan sulfate, and proteases.
- 50. A method of claim 47 wherein said plaque component is β amyloid and said agent is an inactivator of a neurotoxic mononuclear phagocyte.
- 51. A method of claim 47 wherein said plaque component or said mononuclear phagocyte is adhered to a solid support to form an plaque component adhered solid support.
- 52. A method of claim 51 wherein said solid support is selected from a microsphere, liposome, sepharose, and sephadex.
- 53. A method of claim 51 wherein said plaque component is β amyloid and said solid support is a microsphere.
- 54. A method of claim 51 wherein said β amyloid is adhered to a solid support and is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 55. A method of claim 47 wherein said plaque component or said mononuclear phagocyte is labeled.
- 56. A method of claim 55 wherein said label is selected from the group consisting of 32P, 125I, 14C, 3H, 35S, biotin, fluorescein, rhodamine, peroxidase, and antibody labeling.
- 57. A method of claim 47 wherein said step of measuring is selected from the group consisting of observing a loss of metabolic function, release of intracellular material, penetration of impermeant dyes, and reduction of cell number of neurons.
- 58. A method of claim 47 wherein said step of measuring comprises imaging said plaque component induced mononuclear phagocyte neurotoxicity and observing a signal resulting from said imaging.
- 59. A method of claim 47 wherein said step of measuring comprises detecting amplified nucleic acids from said plaque component induced mononuclear phagocyte neurotoxicity.
- 60. A method of claim 47 wherein said plaque component is selected from a patient suspected of having a disease selected from the group consisting of Alzheimer Disease, hereditary hemorrhage with amyloidosis-Dutch type, cerebral amyloid angiopathy, cerebral amyloid angiopathy, Down's syndrome, spongiform encephalopathy, Creutzfeld-Jakob disease, HIV, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, and trauma.
- 61. A method of claim 47 wherein said plaque component or said mononuclear phagocyte is adhered to a solid support to form an plaque component adhered solid support which is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 62. A method of screening for an agent that inhibits plaque component induced neurotoxicity of a mononuclear phagocyte comprising:
contacting a mononuclear phagocyte with an effective amount of a plaque component to stimulate plaque component induced neurotoxicity of a mononuclear phagocyte, wherein said plaque component is coupled to a solid support, and an effective amount of an agent suspected of inhibiting said plaque component induced neurotoxicity of said mononuclear phagocyte for an effective amount of time, measuring plaque component induced neurotoxicity of said mononuclear phagocyte, comparing said measured plaque component induced neurotoxicity of said mononuclear phagocyte to a measured control, wherein reduction of plaque component induced neurotoxicity compared to said control results in detection of an agent that inhibits plaque component induced neurotoxicity of said mononuclear phagocyte.
- 63. A method of screening for an agent that inhibits plaque component induced neurotoxicity of a mononuclear phagocyte comprising:
contacting a mononuclear phagocyte in a mammalian brain with an effective amount of a plaque component to stimulate plaque component induced neurotoxicity, and an effective amount of an agent suspected of inhibiting said plaque component induced neurotoxicity for an effective amount of time, measuring plaque component induced neurotoxicity of said mononuclear phagocyte, comparing said measured plaque component induced neurotoxicity to a measured control, wherein reduction of plaque component induced neurotoxicity compared to said control results in detection of an agent that inhibits plaque component induced neurotoxicity of said mononuclear phagocyte.
- 64. A method of claim 63 wherein said step of measuring is selected from the group consisting of observing a loss of metabolic function, release of intracellular material, penetration of impermeant dyes, and reduction of cell number of neurons.
- 65. A method of claim 63 wherein said plaque component or said mononuclear phagocyte is labeled.
- 66. A method of claim 65 wherein said label is selected from the group consisting of 32P, 125I, 14C, 3H, 35S, biotin, fluorescein, rhodamine, peroxidase, and antibody labeling.
- 67. A method of claim 63 wherein said step of measuring comprises imaging said plaque component induced mononuclear phagocyte neurotoxicity and observing a signal resulting from said imaging.
- 68. A method of claim 47 wherein said step of measuring comprises detecting amplified nucleic acids from said plaque component induced mononuclear phagocyte neurotoxicity.
- 69. A method of claim 47 wherein said mononuclear phagocyte is selected from the group consisting of a microglial cell, a monocyte, a macrophage, and a microglial precursor cell, monocyte precursor cell, a macrophage precursor cell, microglial-like cell, monocyte-like cell, and a macrophage-like cell.
- 70. A method of screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron comprising:
contacting a neuron with an effective amount of a neurotoxin from a plaque component activated mononuclear phagocyte, or a plaque component induced neurotoxic mononuclear phagocyte to stimulate neuronal damage, and an effective amount of an agent suspected of inhibiting said neurotoxin, for an effective amount of time, measuring neuron function, comparing said measured neuron function to a measured control, wherein increase in neuron function compared to said control results in detection of an agent that inhibits the effect of a neurotoxin from a plaque component activated a mononuclear phagocyte on neurons.
- 71. A method of claim 70 wherein said agent is a neurotoxin blocker.
- 72. A method of claim 70 wherein said plaque component is selected from the group consisting of β amyloid and active fragments thereof, α-antichymotrypsin, apolipoprotein A, apolipoprotein E, glycoproteins, heparan sulfate, and proteases.
- 73. A method of claim 70 wherein said plaque component is β amyloid and said agent is a neurotoxin blocker.
- 74. A method of claim 70 wherein said neuron or said neurotoxin is adhered to a solid support.
- 75. A method of claim 74 wherein said solid support is selected from a microsphere, liposome, sepharose, and sephadex.
- 76. A method of claim 74 wherein said solid support is a microsphere and said neurotoxin is adhered to said microsphere.
- 77. A method of claim 70 wherein said neurotoxin is adhered to a solid support and is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 78. A method of claim 70 wherein said step of measuring comprises observing disruption of normal neuron metabolism.
- 79. A method of claim 78 wherein said normal cell metabolism is selected from the group consisting of metabolism of glucose, the production of ATP, maintenance of ion gradients across a cell membrane, protein synthesis, nucleic acid synthesis, and mitochondrial respiration.
- 80. A method of claim 70 wherein said step of measuring comprises detecting amplified nucleic acids from said neuron.
- 81. A method of claim 70 wherein said plaque component is selected from a patient suspected of having a disease selected from the group consisting of Alzheimer Disease, hereditary hemorrhage with amyloidosis-Dutch type, cerebral amyloid angiopathy, cerebral amyloid angiopathy, Down's syndrome, spongiform encephalopathy, Creutzfeld-Jakob disease, HIV, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, and trauma.
- 82. A method of claim 70 wherein said neurotoxin or said neuron is adhered to a solid support and is infused into a mammalian brain selected from the group consisting of primate, rodent, guinea pig, dog, cat, rabbit, and pig.
- 83. A method of screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated a mononuclear phagocyte on neurons comprising:
contacting a neuron with an effective amount of a neurotoxin from a plaque component activated mononuclear phagocyte to stimulate neuronal damage, wherein said neurotoxin is coupled to a solid support, and an effective amount of an agent suspected of inhibiting said neurotoxin, for an effective amount of time, measuring neuron function, comparing said measured neuron function to a measured control, wherein increase in neuron function compared to said control results in detection of an agent that inhibits the effect of a neurotoxin from a plaque component activated a mononuclear phagocyte on neurons.
- 84. A method of screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated a mononuclear phagocyte on neurons comprising:
contacting a neuron in a mammalian brain with an effective amount of a neurotoxin from a plaque component activated mononuclear phagocyte to stimulate neuronal damage, wherein said neurotoxin is coupled to a solid support, and an effective amount of an agent suspected of inhibiting said neurotoxin, for an effective amount of time, measuring neuron function, comparing said measured neuron function to a measured control, wherein increase in neuron function compared to said control results in detection of an agent that inhibits the effect of a neurotoxin from a plaque component activated a mononuclear phagocyte on neurons.
- 85. A method of claim 84 wherein said step of measuring comprises observing disruption of normal neuron metabolism.
- 86. A method of claim 85 wherein said normal cell metabolism is selected from the group consisting of metabolism of glucose, the production of ATP, maintenance of ion gradients across a cell membrane, protein synthesis, nucleic acid synthesis, and mitochondrial respiration.
- 87. A method of claim 84 wherein said step of measuring comprises detecting amplified nucleic acids from said neuron.
- 88. A method of claim 84 wherein said mononuclear phagocyte is selected from the group consisting of a microglial cell, a monocyte, a macrophage, and a microglial precursor cell, monocyte precursor cell, a macrophage precursor cell, microglial-like cell, monocyte-like cell, and macrophage-like cell.
- 89. A method of screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron comprising:
contacting a mononuclear phagocyte with an effective amount of a plaque component to stimulate mononuclear phagocyte-plaque component complex formation, and an effective amount of an agent suspected of inhibiting said complex formation, for an effective amount of time, measuring of mononuclear phagocyte-plaque component complex formation, comparing said measured mononuclear phagocyte-plaque component complex formation to a measured control, wherein reduction of mononuclear phagocyte-plaque component complex formation compared to said control results in detection of an agent that inhibits mononuclear phagocyte-plaque component complex formation, and isolating a mononuclear phagocyte from an inhibited mononuclear phagocyte-plaque component complex formation, contacting a mononuclear phagocyte from an inhibited mononuclear phagocyte-plaque component complex with an effective amount of a plaque component to stimulate plaque component activation of said mononuclear phagocyte, and an effective amount of an agent suspected of inhibiting said activation, for an effective amount of time, measuring plaque component activation of said mononuclear phagocyte, comparing said plaque component activation of said measured mononuclear phagocyte to a measured control, wherein reduction of plaque component activation of said mononuclear phagocyte compared to said control results in detection of an agent that inhibits plaque component activation of said mononuclear phagocyte and isolating a mononuclear phagocyte which is plaque component activation inhibited, contacting a mononuclear phagocyte which is plaque component activation inhibited with an effective amount of a plaque component to stimulate plaque component induced neurotoxicity, and an effective amount of an agent suspected of inhibiting said plaque component induced neurotoxicity for an effective amount of time, measuring plaque component induced neurotoxicity, comparing said measured plaque component induced neurotoxicity to a measured control, wherein reduction of plaque component induced neurotoxicity compared to said control results in detection of an agent that inhibits a plaque component induced neurotoxic mononuclear phagocyte and isolating a plaque component induced neurotoxic mononuclear phagocyte, contacting a neuron with an effective amount of a neurotoxin from a plaque component activated mononuclear phagocyte, or a plaque component induced neurotoxic mononuclear phagocyte to stimulate neuronal damage, and an effective amount of an agent suspected of inhibiting said neurotoxin, for an effective amount of time, measuring neuron function, comparing said measured neuron function to a measured control, wherein an increase in neuron function compared to said control results in detection of an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron.
- 90. A method of screening for an agent that inhibits plaque component induced neurotoxicity of a mononuclear phagocyte comprising performing the method of claim 1 and isolating a mononuclear phagocyte from an inhibited mononuclear phagocyte-plaque component complex formation, performing the method of claim 24 and isolating a mononuclear phagocyte which is plaque component activation inhibited, and performing the method of claim 47 thereby detecting an agent that inhibits a plaque component induced neurotoxicity of a mononuclear phagocyte.
- 91. An agent identified by the method of claim 1, wherein said agent comprises an HHQK sequence.
- 92. An agent of claim 91 having mononuclear phagocyte-plaque component complex formation inhibitory activity.
- 93. A composition comprising an HHQK-like molecule that inhibits a mononuclear phagocyte-plaque component complex in a pharmaceutically acceptable carrier.
- 94. An agent identified by the method of claim 47, wherein said agent comprises a chloroquine-like activity.
- 95. An agent of claim 94 having neurotoxic mononuclear phagocyte inactivator activity.
- 96. A composition comprising a chloroquine-like molecule that inhibits a neurotoxicity of a mononuclear phagocyte induced by a plaque component complex in a pharmaceutically acceptable carrier.
- 97. An agent identified by the method of claim 70, wherein said agent comprises a tyramine-like activity.
- 98. An agent of claim 97 having neurotoxin blocking activity.
- 99. A composition comprising a tyramine-like molecule that inhibits the effects of neurotoxins on neurons in a pharmaceutically acceptable carrier.
REFERENCE TO GOVERNMENT GRANTS
[0001] This work has been supported in part by a grant from the National Institutes of Health, grant number NS25637. The United States Government may have certain rights in this invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08717551 |
Sep 1996 |
US |
Child |
08922930 |
Sep 1997 |
US |